Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin 1 is a radioprotector.

R Neta, S Douches, J J Oppenheim

    Journal of Immunology (Baltimore, Md. : 1950)
    |April 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Recombinant interleukin 1 (IL 1) pretreatment dose-dependently protects mice from lethal radiation doses. This cytokine IL 1 initiates radioprotective events in vivo, suggesting it mediates the effects of other radioprotective immunomodulators.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Interleukin 1 is more than an interleukin.

    Immunology today·2014
    Same author

    There is more than one interleukin 1.

    Immunology today·2014
    Same author

    Alarmins and antimicrobial immunity.

    Medical mycology·2009
    Same author

    Roles of antimicrobial peptides such as defensins in innate and adaptive immunity.

    Annals of the rheumatic diseases·2003
    Same author

    Effects of astragali radix on the growth of different cancer cell lines.

    World journal of gastroenterology·2003
    Same author

    Developing additional resources.

    Radiation and environmental biophysics·2002

    Area of Science:

    • Immunology
    • Radiation Biology
    • Cell Biology

    Background:

    • Interleukin 1 (IL 1) is a cytokine known to induce cell differentiation and maturation.
    • Ionizing radiation poses a significant threat, causing lethal effects in mammals.
    • Exogenous immunomodulators can be radioprotective and often stimulate endogenous IL 1 production.

    Purpose of the Study:

    • To investigate the radioprotective potential of recombinant interleukin 1 (IL 1) in vivo.
    • To determine if IL 1 can initiate radioprotective events following radiation exposure.
    • To explore the role of IL 1 in mediating the effects of other radioprotective agents.

    Main Methods:

    • Mice (C57B1/6 and DBA/1 strains) were pretreated with varying doses of recombinant IL 1.
    • Mice were subsequently exposed to lethal doses of ionizing radiation (LD100/17 or LD50/30).

    Related Experiment Videos

  • Survival rates were monitored to assess the radioprotective efficacy of IL 1.

    • Main Results:

    • Recombinant IL 1 demonstrated dose-dependent radioprotection in mice.
    • 2000 units of IL 1 protected 88% of C57B1/6 mice against an LD100/17 radiation dose.
    • 1000 units of IL 1 protected 100% of DBA/1 mice against an LD50/30 radiation dose.

    Conclusions:

    • Interleukin 1 (IL 1) is the first identified cytokine to initiate radioprotective events in vivo.
    • IL 1's ability to protect against lethal radiation suggests a novel therapeutic application.
    • IL 1 may be the key mediator for the radioprotective effects observed with other immunomodulators.